Equities Analysts Offer Predictions for Qiagen Q1 Earnings

Qiagen (NYSE:QGEN) – Equities research analysts at William Blair decreased their Q1 2025 EPS estimates for Qiagen in a research note issued on Friday, February 7th. William Blair analyst A. Brackmann now anticipates that the company will earn $0.49 per share for the quarter, down from their prior forecast of $0.50. The consensus estimate for Qiagen’s current full-year earnings is $2.28 per share. William Blair also issued estimates for Qiagen’s Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.26 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.66 EPS and FY2026 earnings at $2.43 EPS.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%.

A number of other research firms have also weighed in on QGEN. Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a research note on Thursday, October 17th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $52.50 price target (up from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, UBS Group lowered their price target on Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $48.78.

Qiagen Stock Down 3.0 %

QGEN stock opened at $40.10 on Monday. The company’s 50 day moving average price is $43.74 and its 200 day moving average price is $43.28. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a fifty-two week low of $39.63 and a fifty-two week high of $49.30. The firm has a market capitalization of $8.90 billion, a price-to-earnings ratio of 111.66, a PEG ratio of 3.29 and a beta of 0.36.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently modified their holdings of the stock. State Street Corp lifted its holdings in shares of Qiagen by 3.9% during the third quarter. State Street Corp now owns 2,380,008 shares of the company’s stock worth $108,457,000 after purchasing an additional 90,181 shares during the period. Jennison Associates LLC lifted its holdings in shares of Qiagen by 5.0% during the third quarter. Jennison Associates LLC now owns 1,426,392 shares of the company’s stock worth $65,001,000 after purchasing an additional 68,415 shares during the period. XTX Topco Ltd lifted its holdings in shares of Qiagen by 129.3% during the third quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock worth $920,000 after purchasing an additional 11,385 shares during the period. Sanctuary Advisors LLC lifted its holdings in shares of Qiagen by 24.8% during the third quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company’s stock worth $834,000 after purchasing an additional 3,878 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Qiagen by 36.0% during the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after purchasing an additional 424,937 shares during the period. 70.00% of the stock is owned by institutional investors and hedge funds.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.